194 related articles for article (PubMed ID: 35487730)
1. Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol.
Siltari A; Riikonen J; Koskimäki J; Pakarainen T; Ettala O; Boström P; Seikkula H; Kotsar A; Tammela T; Helminen M; Raittinen PV; Lehtimäki T; Fode M; Østergren P; Borre M; Rannikko A; Marttila T; Salonen A; Ronkainen H; Löffeler S; Murtola TJ
BMJ Open; 2022 Apr; 12(4):e050264. PubMed ID: 35487730
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin induces adrenal androgen downshift in men with prostate cancer: A post Hoc analysis of a pilot adaptive Randomised clinical trial.
Raittinen PVH; Syvälä H; Tammela TLJ; Häkkinen MR; Ilmonen P; Auriola S; Murtola TJ
EBioMedicine; 2021 Jun; 68():103432. PubMed ID: 34144486
[TBL] [Abstract][Full Text] [Related]
3. Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT): study protocol for a randomised phase III trial.
Janssen J; Staal FHE; Brouwer CL; Langendijk JA; de Jong IJ; van Moorselaar RJA; Schuit E; Verzijlbergen JF; Smeenk RJ; Aluwini S
BMC Cancer; 2022 May; 22(1):482. PubMed ID: 35501744
[TBL] [Abstract][Full Text] [Related]
4. Prostate Cancer Survivorship Essentials for men with prostate cancer on androgen deprivation therapy: protocol for a randomised controlled trial of a tele-based nurse-led survivorship care intervention (PCEssentials Hormone Therapy Study).
Green A; Newton RU; Smith DP; Tuffaha H; Galvão DA; Heathcote P; Patel MI; Christie D; Egger S; Sara SA; Heneka N; Chambers SK; Dunn J
BMJ Open; 2024 Mar; 14(3):e084412. PubMed ID: 38521521
[TBL] [Abstract][Full Text] [Related]
5. Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.
Harshman LC; Wang X; Nakabayashi M; Xie W; Valenca L; Werner L; Yu Y; Kantoff AM; Sweeney CJ; Mucci LA; Pomerantz M; Lee GS; Kantoff PW
JAMA Oncol; 2015 Jul; 1(4):495-504. PubMed ID: 26181260
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiotherapy (SBRT) versus androgen deprivation therapy (ADT) for oligometastatic prostate cancer: protocol for a prospective randomised control clinical trial.
Zhao X; Wang T; Ye Y; Li J; Gao X; Zhang H
BMJ Open; 2022 Sep; 12(9):e051371. PubMed ID: 36180115
[TBL] [Abstract][Full Text] [Related]
7. The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy.
Hamilton RJ; Ding K; Crook JM; O'Callaghan CJ; Higano CS; Dearnaley DP; Horwitz EM; Goldenberg SL; Gospodarowicz MK; Klotz L
Eur Urol; 2021 Apr; 79(4):446-452. PubMed ID: 33390282
[TBL] [Abstract][Full Text] [Related]
8. Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial.
Connor MJ; Shah TT; Smigielska K; Day E; Sukumar J; Fiorentino F; Sarwar N; Gonzalez M; Falconer A; Klimowska-Nassar N; Evans M; Naismith OF; Thippu Jayaprakash K; Price D; Gayadeen S; Basak D; Horan G; McGrath J; Sheehan D; Kumar M; Ibrahim A; Brock C; Pearson RA; Anyamene N; Heath C; Shergill I; Rai B; Hellawell G; McCracken S; Khoubehi B; Mangar S; Khoo V; Dudderidge T; Staffurth JN; Winkler M; Ahmed HU
BMJ Open; 2021 Feb; 11(2):e042953. PubMed ID: 33632752
[TBL] [Abstract][Full Text] [Related]
9. Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol.
Kvorning Ternov K; Sønksen J; Fode M; Lindberg H; Kistorp CM; Bisbjerg R; Palapattu G; Østergren PB
BMJ Open; 2019 Sep; 9(9):e030218. PubMed ID: 31511288
[TBL] [Abstract][Full Text] [Related]
10. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
Armstrong AJ; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Shore ND; Rosbrook B; Sugg J; Baron B; Chen L; Stenzl A
J Clin Oncol; 2019 Nov; 37(32):2974-2986. PubMed ID: 31329516
[TBL] [Abstract][Full Text] [Related]
11. A multicentre randomised controlled trial of a guided self-help cognitive behavioural therapy to MANage the impact of hot flushes and night sweats in patients with prostate CANcer undergoing androgen deprivation therapy (MANCAN2).
Crabb S; Morgan A; Hunter MS; Stefanopoulou E; Griffiths G; Richardson A; Fenlon D; Fleure L; Raftery J; Boxall C; Wilding S; Nuttall J; Eminton Z; Tilt E; O'Neill A; Bacon R; Martin J
Trials; 2023 Jul; 24(1):450. PubMed ID: 37430353
[TBL] [Abstract][Full Text] [Related]
12. Phase II proof-of-concept study of atorvastatin in castration-resistant prostate cancer.
Rushworth LK; Loveridge C; Salji M; MacLeod M; Mui E; Sumpton D; Neilson M; Hedley A; Alexander L; McCartney E; Patel R; Wallace J; Delles C; Jones R; Leung HY
BJU Int; 2023 Feb; 131(2):236-243. PubMed ID: 35844167
[TBL] [Abstract][Full Text] [Related]
13. Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database.
Dambal S; Howard LE; Allott EH; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ
J Urol; 2020 Jan; 203(1):120-127. PubMed ID: 31430247
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN;
Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study.
Peltomaa AI; Raittinen P; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):917-924. PubMed ID: 33790420
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of a multi-component exercise programme and nutritional supplementation on musculoskeletal health in men treated with androgen deprivation therapy for prostate cancer (IMPACT): study protocol of a randomised controlled trial.
Owen PJ; Daly RM; Livingston PM; Mundell NL; Dalla Via J; Millar JL; Fraser SF
Trials; 2017 Oct; 18(1):451. PubMed ID: 28974267
[TBL] [Abstract][Full Text] [Related]
18. Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study.
Stenzl A; Dunshee C; De Giorgi U; Alekseev B; Iguchi T; Szmulewitz RZ; Flaig TW; Tombal B; Morlock R; Ivanescu C; Ramaswamy K; Saad F; Armstrong AJ
Eur Urol; 2020 Oct; 78(4):603-614. PubMed ID: 32336645
[TBL] [Abstract][Full Text] [Related]
19. Intermittent androgen deprivation therapy in advanced prostate cancer.
Alva A; Hussain M
Curr Treat Options Oncol; 2014 Mar; 15(1):127-36. PubMed ID: 24395278
[TBL] [Abstract][Full Text] [Related]
20. Study protocol for statin web-based investigation of side effects (StatinWISE): a series of randomised controlled N-of-1 trials comparing atorvastatin and placebo in UK primary care.
Herrett E; Williamson E; Beaumont D; Prowse D; Youssouf N; Brack K; Armitage J; Goldacre B; MacDonald T; Staa TV; Roberts I; Shakur-Still H; Smeeth L
BMJ Open; 2017 Dec; 7(12):e016604. PubMed ID: 29197834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]